BioPharmSignal logoBioPharmSignal

Biotech News

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Exagen (XGN)ExagenEarnings

CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026.

Related news

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

DGXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SERASera Prognostics2026-07-29 20:05 EST

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

BRLIBio-Reference Laboratories2026-07-27 20:05 EST

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

View all latest news

Exagen

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close
6.59 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States